APO Research
Talk to an analyst

APO RESEARCH · REPORT

Varicella Virus Attenuated Live Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Varicella Virus Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025187 pages

Choose your research edition.

Industry ResearchVaricella Virus Attenuated Live Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Virus Attenuated Live Vaccine Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Varicella Virus Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Virus Attenuated Live Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Virus Attenuated Live Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Varicella Virus Attenuated Live Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Varicella Virus Attenuated Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Varicella Virus Attenuated Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Varicella Virus Attenuated Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Varicella Virus Attenuated Live Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Varicella Virus Attenuated Live Vaccine include GSK, Changsheng, Sanofi, Merck, Biken, Shanghai Institute, Keygen, Green Cross and BCHT, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Varicella Virus Attenuated Live Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Varicella Virus Attenuated Live Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Varicella Virus Attenuated Live Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Varicella Virus Attenuated Live Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Varicella Virus Attenuated Live Vaccine Segment by Company

GSK

Changsheng

Sanofi

Merck

Biken

Shanghai Institute

Keygen

Green Cross

BCHT

Varicella Virus Attenuated Live Vaccine Segment by Type

Child

Adult

Varicella Virus Attenuated Live Vaccine Segment by Application

Government Institution

Private Sector

Other

Varicella Virus Attenuated Live Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Virus Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Virus Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Virus Attenuated Live Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Virus Attenuated Live Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Varicella Virus Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Varicella Virus Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Varicella Virus Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Varicella Virus Attenuated Live Vaccine Industry Trends Table 2. Varicella Virus Attenuated Live Vaccine Industry Drivers Table 3. Varicella Virus Attenuated Live Vaccine Industry Opportunities and Challenges Table 4. Varicella Virus Attenuated Live Vaccine Industry Restraints Table 5. Global Varicella Virus Attenuated Live Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Varicella Virus Attenuated Live Vaccine Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Manufacturers Table 9. Global Varicella Virus Attenuated Live Vaccine Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Varicella Virus Attenuated Live Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Varicella Virus Attenuated Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Varicella Virus Attenuated Live Vaccine Manufacturers, Product Type & Application Table 13. Global Varicella Virus Attenuated Live Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Varicella Virus Attenuated Live Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Child Table 17. Major Manufacturers of Adult Table 18. Global Varicella Virus Attenuated Live Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2026) & (k units) Table 20. Global Varicella Virus Attenuated Live Vaccine Sales by Type (2027-2032) & (k units) Table 21. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Varicella Virus Attenuated Live Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2026) & (k units) Table 25. Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2027-2032) & (k units) Table 26. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Government Institution Table 29. Major Manufacturers of Private Sector Table 30. Major Manufacturers of Other Table 31. Global Varicella Virus Attenuated Live Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2026) & (k units) Table 33. Global Varicella Virus Attenuated Live Vaccine Sales by Application (2027-2032) & (k units) Table 34. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2021-2026) Table 35. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2027-2032) Table 36. Global Varicella Virus Attenuated Live Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2026) & (k units) Table 38. Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2027-2032) & (k units) Table 39. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2021-2026) Table 40. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2027-2032) Table 41. Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Varicella Virus Attenuated Live Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Varicella Virus Attenuated Live Vaccine Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Varicella Virus Attenuated Live Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Varicella Virus Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 48. North America Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 49. Europe Varicella Virus Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 51. Europe Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Varicella Virus Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Varicella Virus Attenuated Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Varicella Virus Attenuated Live Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Varicella Virus Attenuated Live Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region (2021-2026) Table 62. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. GSK Varicella Virus Attenuated Live Vaccine Product Portfolio Table 67. GSK Recent Development Table 68. Changsheng Company Information Table 69. Changsheng Business Overview Table 70. Changsheng Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Changsheng Varicella Virus Attenuated Live Vaccine Product Portfolio Table 72. Changsheng Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi Varicella Virus Attenuated Live Vaccine Product Portfolio Table 77. Sanofi Recent Development Table 78. Merck Company Information Table 79. Merck Business Overview Table 80. Merck Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Merck Varicella Virus Attenuated Live Vaccine Product Portfolio Table 82. Merck Recent Development Table 83. Biken Company Information Table 84. Biken Business Overview Table 85. Biken Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Biken Varicella Virus Attenuated Live Vaccine Product Portfolio Table 87. Biken Recent Development Table 88. Shanghai Institute Company Information Table 89. Shanghai Institute Business Overview Table 90. Shanghai Institute Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Shanghai Institute Varicella Virus Attenuated Live Vaccine Product Portfolio Table 92. Shanghai Institute Recent Development Table 93. Keygen Company Information Table 94. Keygen Business Overview Table 95. Keygen Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Keygen Varicella Virus Attenuated Live Vaccine Product Portfolio Table 97. Keygen Recent Development Table 98. Green Cross Company Information Table 99. Green Cross Business Overview Table 100. Green Cross Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Green Cross Varicella Virus Attenuated Live Vaccine Product Portfolio Table 102. Green Cross Recent Development Table 103. BCHT Company Information Table 104. BCHT Business Overview Table 105. BCHT Varicella Virus Attenuated Live Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. BCHT Varicella Virus Attenuated Live Vaccine Product Portfolio Table 107. BCHT Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Varicella Virus Attenuated Live Vaccine Distributors List Table 111. Varicella Virus Attenuated Live Vaccine Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Varicella Virus Attenuated Live Vaccine Product Image Figure 2. Global Varicella Virus Attenuated Live Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Virus Attenuated Live Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Varicella Virus Attenuated Live Vaccine Sales (2021-2032) & (k units) Figure 5. Global Varicella Virus Attenuated Live Vaccine Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Varicella Virus Attenuated Live Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Child Image Figure 9. Adult Image Figure 10. Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Varicella Virus Attenuated Live Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Government Institution Image Figure 17. Private Sector Image Figure 18. Other Image Figure 19. Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Varicella Virus Attenuated Live Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2021-2032) Figure 22. Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2021-2032) Figure 25. North America Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Varicella Virus Attenuated Live Vaccine Sales Market Share by Country (2021-2032) Figure 27. U.S. Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Varicella Virus Attenuated Live Vaccine Sales Market Share by Country (2021-2032) Figure 32. Germany Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Varicella Virus Attenuated Live Vaccine Sales Market Share by Country (2021-2032) Figure 39. China Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales Market Share by Country (2021-2032) Figure 47. Brazil Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Varicella Virus Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Varicella Virus Attenuated Live Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 58. North America Varicella Virus Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. Europe Varicella Virus Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Varicella Virus Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Varicella Virus Attenuated Live Vaccine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Varicella Virus Attenuated Live Vaccine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Government Institution
  • Private Sector
  • Other
Companies covered
  • GSK
  • Changsheng
  • Sanofi
  • Merck
  • Biken
  • Shanghai Institute
  • Keygen
  • Green Cross
  • BCHT

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Varicella Virus Attenuated Live Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Varicella Virus Attenuated Live Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Varicella Virus Attenuated Live Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Varicella Virus Attenuated Live Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Varicella Virus Attenuated Live Vaccine Market Dynamics
  1. 2.1 Varicella Virus Attenuated Live Vaccine Industry Trends
  2. 2.2 Varicella Virus Attenuated Live Vaccine Industry Drivers
  3. 2.3 Varicella Virus Attenuated Live Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Virus Attenuated Live Vaccine Industry Restraints
3 Varicella Virus Attenuated Live Vaccine Market by Manufacturers
  1. 3.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Varicella Virus Attenuated Live Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Varicella Virus Attenuated Live Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Varicella Virus Attenuated Live Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Varicella Virus Attenuated Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Varicella Virus Attenuated Live Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Varicella Virus Attenuated Live Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Varicella Virus Attenuated Live Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Varicella Virus Attenuated Live Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Varicella Virus Attenuated Live Vaccine Tier 1, Tier 2, and Tier 3
4 Varicella Virus Attenuated Live Vaccine Market by Type
  1. 4.1 Varicella Virus Attenuated Live Vaccine Type Introduction
  2. 4.1.1 Child
  3. 4.1.2 Adult
  4. 4.2 Global Varicella Virus Attenuated Live Vaccine Sales by Type
  5. 4.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Varicella Virus Attenuated Live Vaccine Revenue by Type
  9. 4.3.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2021-2032)
5 Varicella Virus Attenuated Live Vaccine Market by Application
  1. 5.1 Varicella Virus Attenuated Live Vaccine Application Introduction
  2. 5.1.1 Government Institution
  3. 5.1.2 Private Sector
  4. 5.1.3 Other
  5. 5.2 Global Varicella Virus Attenuated Live Vaccine Sales by Application
  6. 5.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032)
  8. 5.2.3 Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Varicella Virus Attenuated Live Vaccine Revenue by Application
  10. 5.3.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2032)
  12. 5.3.3 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2021-2032)
6 Global Varicella Virus Attenuated Live Vaccine Sales by Region
  1. 6.1 Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Varicella Virus Attenuated Live Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Varicella Virus Attenuated Live Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Varicella Virus Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Varicella Virus Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Varicella Virus Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Varicella Virus Attenuated Live Vaccine Revenue by Region
  1. 7.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Region
  2. 7.1.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Varicella Virus Attenuated Live Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Varicella Virus Attenuated Live Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Varicella Virus Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Varicella Virus Attenuated Live Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Varicella Virus Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Varicella Virus Attenuated Live Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Varicella Virus Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Varicella Virus Attenuated Live Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Changsheng
  8. 8.2.1 Changsheng Company Information
  9. 8.2.2 Changsheng Business Overview
  10. 8.2.3 Changsheng Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Changsheng Varicella Virus Attenuated Live Vaccine Product Portfolio
  12. 8.2.5 Changsheng Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Varicella Virus Attenuated Live Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Varicella Virus Attenuated Live Vaccine Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Biken
  26. 8.5.1 Biken Company Information
  27. 8.5.2 Biken Business Overview
  28. 8.5.3 Biken Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Biken Varicella Virus Attenuated Live Vaccine Product Portfolio
  30. 8.5.5 Biken Recent Developments
  31. 8.6 Shanghai Institute
  32. 8.6.1 Shanghai Institute Company Information
  33. 8.6.2 Shanghai Institute Business Overview
  34. 8.6.3 Shanghai Institute Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Institute Varicella Virus Attenuated Live Vaccine Product Portfolio
  36. 8.6.5 Shanghai Institute Recent Developments
  37. 8.7 Keygen
  38. 8.7.1 Keygen Company Information
  39. 8.7.2 Keygen Business Overview
  40. 8.7.3 Keygen Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Keygen Varicella Virus Attenuated Live Vaccine Product Portfolio
  42. 8.7.5 Keygen Recent Developments
  43. 8.8 Green Cross
  44. 8.8.1 Green Cross Company Information
  45. 8.8.2 Green Cross Business Overview
  46. 8.8.3 Green Cross Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Green Cross Varicella Virus Attenuated Live Vaccine Product Portfolio
  48. 8.8.5 Green Cross Recent Developments
  49. 8.9 BCHT
  50. 8.9.1 BCHT Company Information
  51. 8.9.2 BCHT Business Overview
  52. 8.9.3 BCHT Varicella Virus Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BCHT Varicella Virus Attenuated Live Vaccine Product Portfolio
  54. 8.9.5 BCHT Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Varicella Virus Attenuated Live Vaccine Value Chain Analysis
  2. 9.1.1 Varicella Virus Attenuated Live Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Varicella Virus Attenuated Live Vaccine Production Mode & Process
  6. 9.2 Varicella Virus Attenuated Live Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Varicella Virus Attenuated Live Vaccine Distributors
  9. 9.2.3 Varicella Virus Attenuated Live Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst